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ABSTRACT 
USEFULNESS OF DEL NIDO CARDIOPLEGIA IN ADULT CARDIAC SURGERY 
Del Nido cardioplegia is a type of cardioplegic solution widely used for complex congenital 
paediatric cardiac surgery. Its use in adult cardiac surgery is extended now. In our institute 
we are using it for various adult cardiac surgery patients for past one year. In this study 59 
patients who underwent cardiac surgery using del Nido cardioplegia for achieving cardiac 
arrest, on observation it is effective for 60 to 80 minutes in maintaining arrest without 
spontaneous electrical activity need of frequent  dose is less, surgery can be performed 
without work flow interruption. Recovery after cross clamp is smooth need for DC shock is 
very less,  post-operative inotropic support were minimal and post-operative ECG and ECHO 
shows no evidence of perioperative ischemia. From our observation we conclude that it can 
be used safely in adult cardiac surgery patients also according to surgeon’s preference. 
Key words:Del Nido cardioplegia, myocardial protection, DC shock, cardio pulmonary 
bypass. 
INTRODUCTION 
Cardioplegic solution is the means by which the ischemic myocardium is protected from 
cell death. This is achieved by immediate and sustained electromechanical quiescence, rapid and 
sustained homogenous myocardial cooling, maintenance of therapeutic additives in effective 
concentrations and periodic washout of metabolic inhibitors. 
Cardioplegia is an essential requisite for many of the more complex cardiac surgical 
procedures in which the heart must be stopped. It is an integral method of myocardial protection 
for patients of all ages requiring cardiac surgery. Effective myocardial protection remains the 
most important factor deciding on the outcome of the cardiac surgeries. Injury to myocardium 
must be avoided at any cost. 
Introduction of cardioplegic solutions, beginning in the mid-1960s, in its numerous 
variations has found broad clinical application in the field of cardiac surgery. Due to variations in 
institutional experience and individual surgeon’s preference the myocardial protection afforded 
by various cardioplegic solutions differs as its composition. 
There are many cardioplegic solutions such as St. Thomas' Solution, Bretschneider 
Solution,University of Wisconsin Solution, Custodiol HTK, Celsior., del Nido. The only vital 
additive in most solutions is potassium chloride in a 20-30 mmol/L concentration range. Other 
additives such as mannitol, sodium bicarbonate, procaine are of secondary importance. In the 
early 1990s, del Nido cardioplegia ,a formulation was developed by the team, led by Pedro del 
Nido, Hung Cao-Danh, K.Eric Sommers and Akihiko Ohkado researchers at the University of 
Pittsburgh originally for the paediatric and infant cardiac surgeries. Its use in the adult cardiac 
surgeries is expanding now. 
Del Nido cardioplegia requires less frequent dosing and has potential benefits in adult 
cardiac surgery and minimally invasive valve surgery which include decreased workflow 
interruptions, shorter aortic cross-clamp and bypass times and has better myocardial protection. 
 
Hence this study is an attempt to evaluate the usefulness of del Nido cardioplegia in adult 
cardiac surgery so as to ascertain the nature of myocardial protection afforded by it which is key 
element in the cardiac surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
AIMS AND OBJECTIVES 
 To  assess the usefulness of del Nido cardioplegia in adult cardiac surgery 
 To evaluate the aortic crossclamp time and bypass time 
 To evaluate whether use of del nido cardioplegia will reduce  the need for 
defibrillation  
 To assess the myocardial protection with the use of del Nido cardioplegia. 
 
 
 
 
 
 
 
 
 
 
 
 
 REVIEW OF LITERATURE  
HISTORICAL PERSPECTIVES IN CARDIAC SURGERY 
 The first successful heart operation was performed by Dr.Ludwig Rehn, a surgeon in 
Frankfurt, Germany. 1.5cm gaping right ventricular wound  was closed in diastole after the 
bleeding was controlled with finger pressure. 
 Dr.Luther Martin Hill was the first American who repaired cardiac wound successfully 
in a 13 year old boy, a victim of multiple stab wounds. 
 Matin Kirschner was the first person to report a case who recovered completely after 
undergoing pulmonary embolectomy. 
 John Gibbon found that only 9 out of 142 who had undergone procedures worldwide 
were alive after the procedure. This made him think about the work on pump oxygenator which 
could maintain circulation. He initiated the use of extracorporeal circulation in open heart 
surgery which made it obvious that aortic cross clamping is necessary for providing bloodless 
field during the repair of intracardiac defects. 
 As there are many controversies in the field of cardiac surgery, there are many 
controversies regarding who is the first person to think in terms of myocardial management and 
myocardial protection. Lillehei et al in 1956 deviced the first special method known as 
retrograde coronary perfusion for surgery on the aortic valve.    
Melrose et al introduced “elective cardiac arrest” by injecting 2.5% potassium citrate 
solution in warm blood into the aortic root after aortic cross-clamping. Development of severe 
myocardial necrosis was associated with this technique. 
Cardiopulmonary bypass 
 Cardiopulmonary bypass is usually in cardiac surgery when the heart has to be arrested 
during surgery. 
                                                   
    A heart lung machine in 1958 
In 1926, the first heart lung machine was developed by Sergei
 
Brukhonenko for total 
body perfusion. In the University of Minnesota Hospital, Dr.Clarenc Dennis and his team 
conducted the first operation, open cardiotomy with mechanical takeover of heart and lungs in 
April, 1951.The patient succumbed because of the congenital heart defect. 
 Forest Dewey Dodrill was the first person to use the mechanical support successfully for 
left ventricular function using a machine called as Dodrill-GMR . 
 John Gibbon on May 6, 1953 performed the first successful open heart procedure in a 
human heart, atrial septal defect closure in a18 year old woman using the heart lung machine at 
Thomas Jefferson University Hospital in Philadelphia.   
 Heart lung machine at present 
 DIAGRAM SHOWING CARDIOPULMONARY BYPASS CIRCUIT 
Oxygenators 
 In the 17
th
 century, Robert Hooke was the first person to conceptualise oxygenator. In 
19
th
 century French and German physiologists developed practical extracorporeal oxygenators. 
Bubble oxygenators are direct contact oxygenators. In membrane oxygenators there is gas 
permeable membrane which decreases the blood trauma of bubble oxygenators. Nowadays high 
performance microporous hollow –fibre oxygenators are present in cardiac theatres replacing the 
old oxygenators. 
Myocardial protection 
 In 1883, antagonistic effects of calcium and potassium ions on cardiac contraction was 
described by Ringer. 
 Hooker reported the successful resuscitation of dogs with ventricular fibrillation by using 
potassium. 
 In 1930, Wiggers  demonstrated that injections of potassium chloride was capable of 
arresting the heart in diastole and abrogating ventricular fibrillation. In addition he demonstrated 
the possibility  of using calcium chloride and massage to revive the heart.  In 1960 – 
Normothermic ischemic arrest was advocated in uncomplicated cases with short ischemic 
periods. Stone heart syndrome was associated with the above said technique. Hence Intermittent 
aortic cross-clamping was attempted which involved the reperfusion of the coronary circulation 
for 5 minutes following 15minutes of ischemic arrest. 
 Later it became evident that intermittent reperfusion for normothermic ischemic periods 
up to 60 minutes has neither functional nor metabolic advantages. In spite of this Intermittent 
cross clamping with ventricular fibrillation continues to be used for coronary artery bypass 
surgery. 
Fibrillatory arrest  
 Glenn, Sewell and Senning – to avoid air embolism electrically induced ventricular 
fibrillation with coronary perfusion. Subendocardial ischemia and necrosis was demonstrated by 
Buckberg et al nad Hottenrott et al with this technique. 
Continuous Coronary Perfusion 
  McGoon et al demonstrated that continuous coronary perfusion with a beating heart at 
normothermia or mild hypothermia at 32
0
C to prevent the onset of ventricular fibrillation. This 
technique is being used even today for complex aortic root surgery or for the special situations 
such as redo mitral valve surgery. 
Hypothermia 
 Before the heart – lung machine came into scene, hypothermia was produced by surface 
cooling to protect the heart, brain and other organs during circulatory arrest. 
 Bigelow et al suggested the use of hypothermia as a form of anaesthesia to permit the 
surgeon to operate on a bloodless heart without recourse through extra corporeal pumps. 
 Shumway et al introduced profound local (topical) hypothermia, technique which 
involved the filling of pericardial sac with ice-cold saline. It is still used as an adjunct to other 
methods of myocardial protection.  
 
 
Reintroduction of Cardioplegia 
 Bretschneider reported the principle using a low-sodium, calcium free solution to arrest 
the heart. 
St.Thomas solution was developed by Hearse et al who studied the various components 
of cardioplegic solution. The components of this crystalloid solution is normal concentrations 
sodium and calcium with the addition of potassium chloride (16mmol/L) and magnesium 
chloride (16mmol/L) to arrest the heart immediately. 
In 1975,at St.Thomas Hospital, Braimbridge and colleagues introduced this solution in 
clinical practice. 
Lower concentration of potassium chloride afforded the same degree of myocardial 
protection was demonstrated by Gay and Ebert experimentally. 
In 1977, satisfactory protection in over 100 cardiac cases was demonstrated with 
potassium cardioplegia by Tyres et al. 
The major controversy in 1980s was regarding the ideal composition of cardioplegic 
solution. 
The chief variants at that time are 
 Bretschneider solution – sodium, magnesium and procaine 
 St.Thomas solution – Potassium, magnesium and procaine added to ringer,s 
solution 
 Potassium-enriched solutions with no magnesium or procaine. 
Blood cardioplegia was introduced coincidently. 
 
 
 
 
MYOCARDIAL PROTECTION  
The goals of myocardial protection are 
 To protect against ischemic injury 
 To provide a motionless, bloodless field 
 Allow effective post-ischemic myocardial resuscitation  
CARDIOPLEGIA 
  Cardioplegia is a solution which contains a variety of chemical substances designed to 
 Arrest the heart in diastole rapidly 
 Create quiescent operating field 
 Provide reliable protection against ischemia – reperfusion injury 
Principles of Cardioplegic Protection 
Arrest 
 Rapid and effective induction of arrest in diastole. To keep the heart arrested in relaxed 
state and to minimise the use of intracellular ATP. 
Myocardial protection 
  To limit the reperfusion injury and to delay the occurrence of irreversible injury. 
Reversibility 
 Prompt recovery of normal cardiac function from the effect of cardioplegia 
Low toxicity 
 No toxic effects on other organs 
Mechanism of action of Cardioplegia 
In most of the cardioplegic solutions , the high potassium concentration present decreases 
the resting membrane potential of cardiac cells. The normal resting membrane potential of 
ventricular myocyte is approximately -90mv. The channels which are present in the cell 
membrane has been tabulated as given below 
 
PHYSIOLOGY OF ION CHANNELS PRESENT IN A CARDIAC MYOCYTE 
 
 
Current Channel Gating mechanism Functional role 
iK1 
  
K
+
 channel (inward 
rectifier) 
  
Voltage gated channel 
Maintains high K
+
 permeability 
during phase 4 
Its decay contributes to diastolic 
depolarization 
Its suppression during phases 0 to 2 
contribute to plateau 
iNa 
  
Na
+
 channel (fast) 
  
Voltage gated channel 
Accounts for phase 0 of action 
potential 
Inactivation may contribute to phase 1 
of action potential 
iTo 
  
K
+
 channel 
(transient outward) 
  
Voltage gated channel 
Contributes to phase 1 of action 
potential 
iCa 
  
Ca
2+
 channel (slow 
inward, L channels) 
  
Voltage gated channel 
Primarily responsible for phase 2 of 
action potential 
Inactivation may contribute to phase 3 
of action potential 
Is enhanced by sympathetic 
stimulation and -adrenergic agents 
iK 
  
K
+
 channel (delayed 
rectifier) 
  
Voltage gated channel 
Causes phase 3 of action potential 
May be enhanced by increased 
intracellular Ca
2+ 
iKATP 
  
K
+
 channel (ATP-
sensitive) 
  
Ligand gated channel 
Increases K
+
 permeability when 
[ATP] is low 
  
iKACh 
  
K
+
 channel 
(acetylcholine-
activated) 
  
Ligand gated channel 
Responsible for effects of vagal 
stimulation 
Decreases diastolic depolarization 
(and heart rate) 
Hyperpolarizes resting membrane 
potential 
Shortens phase 2 of the action 
potential 
if("funny") 
  
Na
+
 channel 
(pacemaker current) 
  
Both 
Contributes to the diastolic 
depolarization 
Is enhanced by sympathetic 
stimulation and -adrenergic agents 
Is suppressed by vagal stimulation 
 
 
 
When the blood surrounding the cardiac myocytes are being replaced by a cardioplegic 
solution with high potassium concentrated solution prevents repolarisation. The cardiac myocyte 
are inexcitable to ordinary stimuli by raising the potassium concentration to 16.6mmol/l raises 
the resting membrane potential to -60mv. 
The other cations Na+ and Ca2+, can be used to cause cardioplegia. However the 
removal of Na+ ions will not let the action potential to occur but at the same time the resting 
membrane potential will not be altered. Removal of extracellular Ca2+ results in a cardiac arrest 
in diastole due to decrease in heart’s contractility. Stone heart or rigor will result when the Ca2+ 
concentration is elevated. 
Types of cardioplegia 
 Crystalloid cardioplegia 
 Blood cardiplegia 
Crystalloid cardioplegia 
 It was introduced with the aim to provide cardioprotection and to provide a bloodless 
field to the surgeons. The ingredients varies in different solutions and rationale is behind these 
ingredients is 
 Rapid induction of cardiac arrest 
 Conservation of intracellular ATPs 
 Maintain intracellular homeostasis 
 Reduce myocardial oxygen consumption 
 Enhance energy production by both aerobic and anaerobic pathway 
 Stabilisation of pH using buffers 
  Hypocalcemic environment and adding magnesium 
 Addition of mannitol to maintain normal oncotic pressure and to prevent cellular edema 
 
Types of crystalloid cardioplegia 
 Intracellular type 
  Absent or low concentration of sodium and calcium 
 Extracellular type  
 Higher concentration of sodium, calcium and magnesium 
Cold blood cardioplegia 
  This cardioplegia uses blood as a vehicle for hypothermic potassium – induced cardiac 
arrest. Basis for using blood is 
 It provides an oxygenated environment  
 Intermittent reoxygenation during cardiac arrest 
 Limits hemodilution 
 Buffering capacity is better than crystalloid cardioplegia 
 Presence of endogenous antioxidants and free-radical scavengers 
Formulation: 
 Combining autologous blood in extracorporeal circuit with the crystalloid cardioplegic 
solution that contains citrate – phosphate – dextrose, tris-hydroxymethylaminomethane or 
bicarbonate and potassium chloride. Rapid arrest is by initial induction followed by intermittent 
or continuous infusion. Ratio of blood to crystalloid varies among centres from 8:1, 4:1, and 2:1. 
Miniplegia 
 Use of undiluted blood cardioplegia is called as miniplegia. 
 Petrucci  and his colleagues studied the use of blood miniplegia in comparison with 
crystalloid cardioplegia and concluded that use of blood miniplegia is superior in acutely 
ischemic heart. 
 Velez and colleagues found that an all blood cardioplegia with ratio of 66:1 is superior to 
4:1 blood cardioplegia delivered in a retrograde fashion 
 Rousou et al. found that it is the level of hypothermia that is important and not 
necessarily the haematocrit. 
 Many studies indicate the fact that cold blood cardioplegia is superior to cold crystalloid 
cardioplegia. Contrary to the abovesaid fact there are studies which have shown that crystalloid 
cardioplegia offers better cardioprotecction compared with that of blood cardioplegia and it is 
said to be cost effective. 
 In 2006, Guru and his colleagues reported a lower incidence of low cardiac output 
syndrome and CK-MB release in patients with cold blood cardioplegia in comparison with 
crystalloid cardioplegia. 
 An analysis of clinical data by Jacob et al. showed 8 trials favouring blood cardioplegia 
and 5 showed significant differences favouring one over the other.  
Warm Blood Cardioplegia 
 In 1982, Rosenkranz et al reported that induction  with normothermic warm blood 
cardioplegia which was then supplemented with multidoses of intermittent cold blood 
cardioplegia was found to be better cardioprotective than cold blood cardioplegia. 
 Teoh et al in 1986 came up with an experimental evidence that warm blood cardioplegia 
just before removing the cross clamp was more cardioprotective than other methods. 
In 1991, Lichetenstein and colleagues reported that normothermic  blood cardioplegia is 
an effective cardioprotective approach in humans. 
Tepid blood cardioplegia 
 Hayashida et al as attempt to find an optimum temperature as there were many 
advantages and disadvantages for both warm and cold cardioplegia, found specifically efficient 
tepid blood cardioplegia at 29
o
C. In this study 72 patients undergoing CABG were randomly 
assigned to receive either antegrade or retrograde warm cardioplegia at 37
o
C or antegrade or 
retrograde cold cardioplegia at 8
o
C or antegrade or retrograde tepid cardioplegia at 29
o
C. The 
myocardial protection afforded by the three were equivocal whereas tepid antegrade cardioplegia 
was effective in reducing lactate release by anaerobic glycolysis. 
 Though there are many single centred studies supporting the use of tepid blood 
cardioplegia but long term study with more number of subjects is yet to come for the proof of it 
to be the most effective. 
Type of cardioplegia Advantages Limitations 
Crystalloid Inexpensive 
Availability 
Simplicity 
Large volume of crystalloid 
No buffering or oxygen 
carrying capacity 
Blood Presence of blood buffers 
Presence of antioxidants 
Oxygen carrying capacity 
Complex procedure and cost 
Tchnique Advantages Limitations  
Microplegia Large volume but minimal 
crystalloid  
Ability to modify and quantify 
the additives 
Complex procedure 
 
Methods of delivery    
 As there are many controversies in the temperature there are controversies in the method 
of delivery too. The various methods by which it can be delivered are as follows 
 Intermittent antegrade 
 Antegrade via the graft 
 Continuous antegrade 
 Continuous retrograde 
 Intermittent retrograde 
 Antegrade followed by retrograde 
 Simultaneous antegrade and retrograde 
All these methods are equally good and the comparison is a cumbersome process with 
numerous confounding factors such as composition and temperature of the cardioplegia, 
duration of infusion, pressure at which the infusion is delivered, type and complexity of 
the surgical method, the expected aortic cross clamp time. 
 
  Retrograde technique is the most frequently used method of delivery. In 1898, Pratt 
showed that ischemic myocardium could be supplied with oxygenated blood via coronary 
venous system. Retrograde coronary sinus perfusion was used by Lillihei and his colleagues 
for aortic valve surgeries 60 years later. 
 The advantages of retrograde cardioplegia are 
 Aortic root and valve surgery 
 Decreased risk of embolization from the saphenous grafts 
 Continuous delivery of cardioplegia 
The limitations of retrograde cardioplegia is that there is heterogenecity in the 
distribution of cardioplegia due to the variations in the anatomy of coronary sinus morphology 
and the fact that right ventricle is not drained by coronary sinus. 
 Ihnken et al reported the feasibility and safety of administering both antegrade and 
retrograde cardioplegia. Sonicated albumen and transesophageal echocardiography was done 
intraoperatively by Cohen and colleagues and they demonstrated that anterior left and right 
ventricles were perfused in a simultaneous technique using both routes of administration. 
Cardioplegia delivery techniques 
Technique Advantages Limitations 
Antegrade  Simple 
 Resembles normal coronary flow 
 Aortic valve must be 
competent 
 Advanced CAD 
Retrograde  Can be preferred in aortic 
insufficiency and advanced CAD 
 Does not impede the conduct of case 
 Augments deairing 
 Placement of catheter is 
difficult 
 Complex 
Through 
conduits 
 Allows antegrade protection of areas 
of CAD 
 Obviates limitations from aortic 
insufficiency and advanced CAD 
 Allows delivery without need to 
 Conduits are required 
 Complex 
 Right coronaries are not 
perfused properly 
pressurise aortic root or interrupt 
surgery 
Integrated  More uniform distribution of 
cardioplegia 
 Complexity 
 
 In comparison with the intermittent and continuous method of administration, 
intermittent has the ability to achieve and sustain a quiescent heart preoperatively. The 
continuous system has an advantage of reducing ischemia if it is oxygenated.   
 
Technique Advantages Limitations 
Intermittent  Improved exposure 
 Lower cardioplegia 
volume 
 Increased interdose 
myocardial acidosis 
Continuous   Normal perfusion 
 Increased 
postoperative LV 
performance 
 Decreased 
postoperative 
inotropic requirement  
 Operative field will 
not be dry 
 Complex 
 
Cardioplegia additives 
Nicorandil 
 Potassium has a deleterious effect to the coronary vascular endothelium. Nicorandil , an 
adenosine triphosphate sensitive potassium channel opener KATP. The advantages of using 
nicrandil are as follows 
 Selective KATP  channel opener, cardiac arrest is achieved with minimal dose of 
cardioplegia. 
 Protective against peroperative coronary vasospasm 
 Preconditioning agent. 
Hayashi and colleagues demonstrated that when people received multiple doses of nicorandil, 
they required less doses of cardioplegia. They were also found to recover spontaneously and less 
postoperative segmental S-T changes. They had lower levels of malondialdehyde, creatine kinase 
band and required less doses of catecholamines postoperatively. 
L-Arginine 
 L-Arginine is a nitric oxide donor. 
 Carrier and his colleagues were able to demonstrate that with the use of L-Arginine, the 
enzyme released by myocardium was found to be reduced. 
Reduction in the levels of postoperative myocardial enzymes  and post operative cytokine 
release were noted by Colagrande etal. 
Insulin 
  Insulin is added as adjunct to cardioplegia to improve the myocardial performance. 
Infusion of insulin-glucose-potassium solutions to mitigate the infarct changes in the 
myocardium. 
 Rao et al in their randomised control study conclude that insulin enhanced cardioplegia is 
not superior in providing myocardial protection compared to the noninsulin preparations  
 
CARDIOPLEGIC ADDITIVES 
Additive Advantages  Limitations  
Nicorandil  Requirement of less 
cardioplegia 
 Requirement of less 
potassium chloride 
 Decreased perioperative 
coronary vasospasm 
 Preconditioning agent 
 Reduction in the dosages of 
postoperative 
catecholamines 
 Cost  
L-arginine  Decreased myocardial 
enzyme release 
 Cost  
 Complexity  
 Decreased postoperative 
cytokine levels 
 Decreased pulmonary 
artery wedge pressure 
Insulin  Some studies document 
improvement in 
myocardial perrformance 
 Complexity  
 Efficacy not clear 
 
 
DAMAGE FROM GLOBAL MYOCARDIAL ISCHEMIA 
There are substantial evidence stating that ischemic injury can result irreversible damage 
known as myocardial necrosis when there is ischemia as little as 20 minutes to the 
subendocardium. Studies have also indicated heterogenicity in the behaviour of the myocardial 
cells to ischemia in their ability to switch from aerobic to anaerobic metabolism. 
Global myocardial ischemia is a term used to describe a situation when the aorta is 
clamped and the myocardium is devoid of blood supply except minimally from non-coronary 
source. 
 
MYOCARDIAL STUNNING 
 Prolonged period of both systolic and diastolic dysfunction without muscle necrosis is 
myocardial stunning. Duration may vary from minutes to days. It may be related to incomplete 
reperfusion of microvasculature. They respond well to inotropics indicating the presence of 
ATPs. It may due to the injury caused by free-radicals which could be averted by use free-radical 
scavengers. 
 
MYOCARDIAL HIBERNATION 
 It is a condition in which both perfusion and contraction are low. Here it is a segmental 
contractile dysfunction which is chronic in nature. It is due to decrease in calcium ion transients 
at a cellular level 
. 
 
DEL NIDO CARDIOPLEGIA 
History of del Nido cardioplegia 
Initially, cardioplegia was the same for adults, infants and paediatric patients. The flow, 
volume and pressure were adjusted in accordance to the body weight appropriately. St.Thomas 
cardioplegia solution was used widely in 1980 and 1990 and still being widely used. Researchers 
at University of Pittsburgh felt the need for a cardioplegic solution specific for the paediatric and 
infant cardiac patients especially to address the needs of an immature heart. 
There were many contradictions described reporting that immature heart is both better 
tolerant than adult heart and less tolerant to ischemia than an adult heart. There were 
contradictions regarding the use of St.Thomas solution also with some studies reporting that 
there is no difference between the adult and paediatric heart and some presenting with the fact 
that it is ineffective. Further it was shown experimentally that the neonatal heart behaved 
differently from an adult to a n ischemic insult while other experimental studies concluded that 
there was no such difference noted between the adult and paediatric heart. 
The above listed contradictions were partly attributed that most of the experiments were 
done in animal models which when transformed into reality had totally a different scenario. 
Supportive theory for the development of del Nido cardioplegia 
 High energy phosphates, maintenance of intracellular ionic and cell membrane 
homeostasis is the basis for normal contractile function of myocardium. This contributes for the 
aerobic metabolism within the cell. Disruption of this intracellular homeostasis leads to  cardiac 
ischemia and irreversible damage to myocardium if the insult ensues. 
 During the arrest period, promotion of anaerobic glycolysis, oxygen free- radicals 
handling intracellularly and prevention of intracellular accumulation of high amounts of calcium 
should be limited or prevented per se in order to preserve the function. 
 Cardioplegic solutions usually create a metabolic arrest coupled with hypothermia. The 
main advantage of using high concentrations of potassium usually to cause myocardial arrest is 
simplicity and rapid onset of action. Further it was realised that hyperpolarised cell has lower 
metabolic demands and has found to have lower accumulation of intracellular calcium ions. 
Polarising agents such as procaine, lidocaine was used along with magnesium which competes 
with calcium. Red blood cells were added in varying proportions to release oxygen and energy 
during that ischemic episode. 
 This del Nido cardioplegia has been prepared with a protocol keeping all the issues above 
said in mind and to address the needs of immature myocardium. 
Crystalloid component of del Nido cardioplegia solution 
1 L plasma – Lyte A  Base solution to which the following things are added 
Mannitol 20% 16.3ml 
Magnesium sulphate 50% 4ml 
Sodium bicarbonate 8.4% 13ml 
Potassium chloride(2mEq/L) 13ml 
Lidocaine 1% 13ml 
 
 
 Base solution of Plasma-Lyte A 
 Base solution in del Nido cardioplegia is Plasma-Lyte A. It has electrolyte composition as 
follows: 
Name of the electrolyte Concentration of the electrolyte 
Sodium 140 mEq/L 
Potassium 5 mEq/L 
Magnesium 3 mEq/L 
Chloride 98 mEq/L 
Acetate 27 mEq/L 
Gluconate 23 mEq/L 
 
pH of the solution is 7.4 which is identical to that of plasma. 
 This crystalloid component is mixed with the blood in the ratio of four parts of crystalloid 
to one part of blood which is fully oxygenated patient whole blood. 
 Though there is no calcium in the base solution, final calcium concentration of calcium 
ion in the cardiopelgia is found to be traces as there will be calcium in the blood which is being 
added. This is found to be beneficial and better than without calcium or normal levels of calcium. 
Mannitol 
 Myocardial injury may occur either during cardioplegic arrest or during subsequent 
reperfusion. This may be partly due to the oxygen- free radicals such as superoxide anion, 
hydrogen peroxide and hydroxyl ion. This will be dealt by the intracellular enzymatic anti-
oxidant systems which will nullify the destructive effect of the free radicals, but they are 
inhibited by the myocardial arrest. Myocardial edema has also been noted. Hence inorderr to 
counteract both i.e., intracellular edema and scavenge the free radicals, mannitol  has been 
added. In Boston’s Hospital where del Nido was formulated and used in paedtric cases, 0.5g/Kg 
mannitol is delivered to the bypass circuit shortly before the removal of the cross clamp. 
Magnesium Sulfate 
 Intracellular calcium concentration is a major factor in relation to myocardial 
contractility. On the other hand if calcium accumulates intracellularly relaxation of myocardium 
will be interrupted, hence magnesium is added to the cardioplegic solution which is an effective 
natural blocker of calcium channels. 
Sodium bicarbonate 
 Anaerobic metabolism has to be supported during the period of cardiac arrest. This 
metabolism i.e., anaerobic glycolysis will be inhibited in the presence of excess of hydrogen 
ions. Sodium bicarbonate which is present in the del Nido cardioplegia will perform the role of 
scavenging the excess hydrogen ions and it will help in promoting the anaerobic metabolism as 
well as in maintaining the intracellular pH. 
 Red blood cells have carbonic anhydrase which will be exchanging hydrogen ions for 
bicarbonate and produce carbon dioxide and water. This role of red blood cells is very important. 
Potassium chloride 
 Rapid arrest and reliable recovery will be produced by hyperkalemia but it has its own 
limitations. The myocardial arrest has been done in a depolarised state which will lead to 
accumulation of intracellular sodium and calcium. Lidocaine is found to inhibit the above said 
mechanism and it is found to prolong the period of electromechanical quiescence. 
 Potassium level in del Nido cardioplegia is found to be 24 mEq/L. 
(0.8 crystalloid component) x (26 MEQ added K
+
* + 5 mEq** Plasmalyte K
+ 
)+(0.2 blood 
component)(4.5mEq/l K
+
***) = 24 mEq/l K
+
. 
* Potassium added to the plasmalyte base solution13 mlor 26mEq. Total solution  
volume 1059ml  
** 5mEq is the potassium concentration in the plasmalyte base solution used to formulate 
 the del Nido solution. 
*** 4.5mEq/L is an estimate of the patients serum potassium level 
Lidocaine 
 It is classified as a sodium channel blocker which is usually as an antiarrhythmic. It 
increases the refractory period of the cardiac myocyte. When cardioplegia is given in an ideal 
environment without washout, the action of lidocaine is prolonged. It prevents the intracellular 
accumulation of sodium and calcium. In 2009, study by O’Brien and his colleagues showed that 
del Nido cardioplegia reduced calcium intracellularly. Hence del Nido cardioplegia because of 
the properties of lidocaine and magnesium, can called as modified depolarising agent. 
Patient blood Additive 
 20% by volume fully oxygenated patient blood is added to del Nido cardioplegia which is 
being delivered. This supports aerobic metabolism for a finite period of time. It  
provides buffering for the anaerobic metabolism as well. Blood is found to improve the coronary 
perfusion during cardioplegia delivery. It preserves the myocardial metabolism as well as it 
myocyte function. It results in less ischemic stress and reperfusion injury. 
 The cardioplegia haematocrit can be calculated as follows 
  Blood component haematocrit x 20% portion 
The delivery haematocrit of del Nido cardioplegia if the 20% blood portion has a 
haematocrit of 30% is 6%. 
Hypothermia 
 Hypothermia decreases oxygen requirement of cardiac myocyte. The delivery method of 
del Nido cardioplegia is usually between 8-12
o
C. 
Cardioplegia protocol in Boston’s Children Hospital  
 Recirculating system of cardioplegia is being used in Boston Children’s Hospital.  
 This system has no direct connection with the bypass circuit and it does not draw 
blood from it directly.  
 The system has a dead space volume of just 1ml.  
 This is an important design consideration.  
 The dead space volume may be equal to significant amount of delivery dose when 
harbouring poorly mixed and room temperature cardioplegia solution.  
  Custom disposable tubing set used in Boston’s children hospital consists of  the following 
 Cardioplegia bag connection line with 0.2µm crystalloid filter 
 Cardioplegia reservoir 
 Pump loop 
 Cooling coil 
 Temperature monitoring site 
 Pressure monitoring site 
 Bubble trap with an integral 270µm filter  
 Delivery is through 14Fr or 18Fr aortic root needle 
Retrograde coronary sinus cardioplegia is being used. 125 ml prime for the entire 
cardioplegia circuit is used. 25 ml is present in the cardiac reservoir which totals to 150ml. 
 Dose 
 Usually given as a single dose as 20 ml/kg usually limited to 1l for patients larger 
than 50kg 
 Additional volume has to be supplemented for hypertrophied hearts such as aortic 
insufficiency or known case of coronary disease or surgeon preference 
 Subsequent doses very rarely given which is subjected to surgeon’s discretion. 
 Four parts of crystalloid to be mixed with 1 part of patient’s blood correctly 
 20ml/kg body weight = total cardioplegia dose(A) 
 Total cardioplegia dose(A) + 150ml = total dose 
 Total dose/5 = amount of blood to be added(B) 
 (Total cardiplegia dose(A) +25ml minimal reservoir volume) – (B blood 
component volume ) = Crystalloid cardioplegia volume(C) in the reservoir before 
the addition of blood that will result in the proper 4:1 mixture 
 The perfusionist will have the proper dose amount, recirculating volume C in the 
reservoir before bypass and then adding volume (B) of the patient whole blood 
once on bypass. 
Delivery  
 It is initiated by the surgeon’s removal of the clamp on the table lines from the outlet 
limb 
 Flow is controlled by the perfusionist. 
 20ml/kg is given over a period of 1-2minutes with a system pressure of 100-200mmHg 
 Cardiplegia flow is adjusted from the initial flow based on the observation of the surgeon 
regarding the heart and electrical activity. 
O’Blenes and colleagues experimentally showed that del Nido cardioplegia results in 
lowering of intracellular calcium during myocardial arrest and less frequent spontaneous 
contractions in senescent rat heart models. 
Charette and his coleagues published a retrospective study which showed no significant 
differences in postoperative  complications with del Nido cardioplegia with their routine 
multidose cardioplegia. 
 Though significant progress has been made in every possible step in the cardiac 
surgery there are many things yet to be discovered such as an ideal cardioplegic solution, 
techniques and delivery methods. The lacunae or the controversies are in part due to the 
complex nature of the behaviour of the myocardium in response to ischemia and reperfusion 
injury. The studies usually do not take into consideration the long term morbidity factors 
such as the manifestations in the cardiac function may take years to appear.   
 
 
 
 
 
 
  
 
MATERIAL AND METHODS 
This prospective study was undertaken in Department of cardiothoracic surgery, Rajiv 
Gandhi Government General Hospital, Madras Medical College, Chennai after obtaining consent 
from the Institutional Ethics Committee, Madras Medical College Chennai. 
 Adult Patients undergoing cardiac surgery using del Nido cardiplegia during the study 
period was studied for the usefulness of del Nido cardioplegia. 
Inclusion Criteria 
All patients undergoing Adult cardiac surgery using del Nido cardioplegia during the 
study period in the age group of 15 – 60 years 
Exclusion Criteria 
Patients with evidence of  
 Age more than 60 years 
In patients more than 60 years of age there will be coexistence of other 
confounding factors such as comorbid conditions which would affect the 
outcome of surgery. 
 Coronary Artery Disease 
In patients with coronary artery disease, previous injury to the 
myocardium due to ischemia or infarction can alter the outcome of surgery. 
 Poor LV function 
Patients with poor left ventricular function will have lower myocardial 
reserve.  
 Hepatic or renal failure 
Methodology 
 The preoperative, peroperative and postoperative details of the patients enrolled for the 
study were collected personally by the investigator. 
 The following parameters were taken into consideration during the study 
 Name, age and sex of the patient 
 NYHA classification preoperatively and postoperatively 
 Cardiopulmonary bypass time 
 Number of del Nido cardioplegic dosages administered during surgery 
 Assessment of  total aortic crossclamp time 
 Requirement of DC shock  - Whether required or not 
 Postoperative ventilator support – Duration of support 
 Postoperative inotropic support  
 Postoperative duration in ICU 
 Postoperative ECHO – Done after 5th postoperative day 
 Total duration(days) postoperatively 
 Mortality(if any) – Cause was evaluated with respect to technical reasons or 
postoperative low cardiac output which was assessed in terms of myocardial protection. 
Statistical Analysis  
Appropriate statistical analytical methods were used. 
  
 
RESULTS 
 In this study dealing with “Usefulness of del Nido cardioplegia in adult cardiac surgery”, 
the details which were observed during the course of the study are summated and given below. 
AGE: 
AGE IN 
YEARS 
NO. OF PATIENTS ENROLLED 
FOR THE STUDY 
less than 20 5 
20- 40 27 
40 - 60 27 
Total 59 
 
 
 
The patients enrolled for the study included 5 patients less than 20 years of age , 27 each 
belonging to 20 – 40 years age group and 40 – 60 years age group respectively.  
 
SEX: 
SEX 
NO. OF PATIENTS ENROLLED FOR 
THE STUDY 
MALE 29 
FEMALE 30 
 
 
  29 male patients and 30 female patients were enrolled for the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
VALVULAR HEART SURGERIES PERFORMED USING DEL NIDO CARDIOPLEGIA 
VALVULAR HEART 
SURGERIES 
NO. OF 
SURGERIES 
PERFORMED PERFORMED 
AVR 8 
DVR 14 
MVR 37 
MVR,OTV 1 
 
 
 
 
 
 
 
 
NEED FOR DEFIBRILLATION 
 Out of 59 valvular heart surgeries performed using del Nido cardioplegia, the need for 
defibrillation was found only in 5 cases. Amongst the 5 cases, 4 were aortic valve replacement 
and 1 was double valve replacement surgery. 
NEED FOR DEFIBRILLATION 
 
 
NEED FOR DEFIBRILLATION AMONGST VALVULAR HEART SURGERIES 
 
 
CARDIOPLUMONARY BYPASS DURATION WHILE USING DEL NIDO 
CARDIOPLEGIA 
 
VALVULAR HEART SURGERY 
MEAN CPB 
DURATION(MIN) 
MITRAL VALVE 
REPLACEMENT 128 
AORTIC VALVE 
REPLACEMENT 182 
DOUBLE VALVE 
REPALCEMENT 217 
 
 
 
   The mean cardiopulmonary bypass duration for mitral valve replacement, aortic valve 
replacement and double valve replacement using del Nido cardioplegia is 128minutes, 182 
minutes and 217 minutes respectively. 
 
 
 
AORTIC CROSS CLAMP TIME FOR VALVULAR HEART SURGERIES USING DEL 
NIDO CARDIOPLEGIA 
VALVULAR HEART SURGERY 
MEAN AORTIC CROSS CLAMP 
TIME(MIN) 
MITRAL VALVE REPLACEMENT 80 
AORTIC VALVE REPLACEMENT 93 
DOUBLE VALVE REPALCEMENT 155 
 
 
 
 The mean aortic cross clamp time while using del Nido cardioplegia for mitral valve 
replacement, aortic valve replacement and double valve replacement is 80 minutes, 93 minutes 
and 155 minutes respectively.  
 
 
 
Number of doses of del Nido cardioplegia during valvular cardiac surgery 
VALVULAR HEART SURGERY NO. OF DOSES OF DEL NIDO CARDIOPLEGIA 
MVR 1.3 
AVR 1.5 
DVR 2.61 
 
 
 
 
 The mean number of doses of del Nido cardioplegia required for adult valvular cardiac 
surgeries such as mitral valve replacement, aortic valve replacement and double valve 
replacement is 1.3, 1.5 and 2.61 respectively.  
 
 
 
 
 
POSTOPERATIVE ICU STAY: 
VALVULAR HEART SURGERY 
MEAN POSTOPERATIVE ICU 
STAY 
MVR 2 DAYS 
AVR 3 DAYS 
DVR 4 DAYS 
 
  
The mean postoperative ICU stay is 2 days, 3days and 4 days  for Mitral valve replacement, 
aortic valve replacement and double valve replacement respectively 
 
 
POSTOPERATIVE ECG: 
 Postoperatively ECG did not show any evidence of peroperative ischemic insult such as 
development of Q wave or any other significant changes consistent with the development of 
cardiac ischemia. 
POSTOPERATIVE ECHO: 
 No Regional wall motion abnormality was detected in postoperative cases which 
indicates a good myocardial protection. 
MORTALITY: 
 Out of 59 cases in which del Nido cardioplegia was used as an agent to arrest the heart 
while on cardiopulmonary bypass, 7 deaths were noted. The cause of death in all the 7 cases 
were primarily not attributed to use of del Nido cardioplegia.  
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 In our institution, cardiac surgeries such as Mitral Valve Replacement, Aortic Valve 
Replacement or Double Valve Replacement, repair of adult congenital cardiac defects and 
CABG are being routinely performed. This study deals with usefulness of del Nido cardioplegia 
in adult cardiac surgery being performed in the Department of Cardiothoracic Surgery.  
       Adult valvular cardiac surgeries are done under cardiopulmonary bypass in arrested heart. 
To arrest the heart different cardioplegic solutions are being used. St.Thomas cardioplegic 
solution is being routinely used by us to produce cardioplegic arrest. St.Thomas cardioplegic 
solution is a multidose cardioplegia which has to repeated every 20 to 30 minutes during surgery. 
It contains the following composition 
Procaine hydrochloride 13.64mg 
Potassium chloride 59.65mg 
Magnesium chloride 162.65mg 
Sodium metabisulfphite 2mg 
Disodium edetate 0.1mg 
Water for injection  1ml 
 
This cardioplegia has blood to crystalloid in the ratio of 4:1. It is given as cold blood 
cardioplegia at a temperature between 15 – 20oC 
  For the past 1 year, del Nido cardioplegic solution has been is in use for the adult valvular 
cardiac surgeries as some surgeons prefer it as it has duration longer than multidose cardioplegia.   
. 
 This study, which deals with the usefulness of del Nido cardioplegia in adult cardiac 
surgery has been conducted in the Department of Cardiothoracic Surgery from March 2013 to 
March 2014. 
Background for this study 
This study has been taken with the background from the observations of Gregory S.Matte 
et al which reported beneficial effects of del Nido cardioplegia a unique solution which 
comprises of four parts of crystalloid to one part of whole blood mostly as a single dose in 
paediatric congenital cardiac surgeries.  
In Virginia Commonwealth University,R Ramanathan et al conducted a retrospective 
analysis of adult patients who underwent cardiac surgeries using del Nido cardioplegia and 
Buckberg’s cardioplegia and compared their outcomes taking a subset of mitral valve surgeries 
in them. Results demonstrated that del Nido cardioplegia has potentially more benefits such as 
fewer doses of cardioplegia and less need for defibrillation compared to that of Buckberg’s 
cardioplegia. 
 59 adult patients with the valvular lesions in the age group from 15 – 60 years were 
enrolled in this study. Patients aged above 60 years were excluded from study because of the 
possibility of coexisting co morbid conditions which could alter the outcome of the surgery.  
The patients enrolled for the study included 5 patients less than 20 years of age, 27 each 
belonging to 20 – 40 years age group and 40 – 60 years age group respectively.  
Out of 59 patients , 29 male patients and 30 female patients were enrolled for the study. 
 During valvular heart surgery, the patient was put on cardiopulmonary bypass .Del Nido 
cardioplegia was used for induction of cardioplegia in all the patients enrolled in the study. 
Del Nido cardioplegia is an in house preparation which has the following composition 
Ringer lactate 800 ml 
Potassium chloride2mEq/ml 13ml 
Mannitol 20% 16.3ml 
Magnesium sulphate 50% 4ml 
Sodium bicarbonate 1mEq/ml 13ml 
Lidocaine 1% 13ml 
  
 The above crystalloid is mixed with blood in the ratio of crystalloid 4parts is to 1 part of 
whole blood.  
 After establishing cardiopulmonary bypass, core cooled to 32
o
C, aortic cross clamp is 
applied and del Nido cardioplegia is given as antegrade cold cardioplegia in a temperature of 15 - 
20
 o
C. The dosage is adjusted to bodyweight i.e, 20ml/Kg of body weight. Initially it is given at a 
pressure of 100mmHg for about 2 minutes followed by 40mmHg for about 4 minutes.  The 
Cardioplegia dose is repeated after an interval of about 60 – 70 minutes as and when required 
according to the electrical activity of the heart.  
 In this study, it was found that with the mean total cardiopulmonary bypass time for 
Mitral Valve Replacement, Aortic Valve Replacement and Double Valve Replacement is 
128minutes, 182 minutes and 217 minutes respectively. 
 The mean aortic cross clamp time is Mitral Valve Replacement, Aortic Valve 
Replacement and Double Valve Replacement is 80 minutes, 93 minutes and 155 minutes 
respectively. 
The mean number of doses of del Nido cardioplegia required for adult valvular cardiac 
surgeries such as mitral valve replacement, aortic valve replacement and double valve 
replacement is 1.3, 1.5 and 2.61 respectively.  
In this study, the number of doses of del Nido cardioplegia needed for the valvular heart 
surgeries is less because it has cardioplegic effect for about 60 minutes which is considered to be 
the likely duration of most single valvular replacement surgeries. This is highly advantageous 
during surgery because there is less work flow interruptions compared to the routinely used 
conventional multidose cardioplegia which has duration of about 20 minutes.   
When multidose cardioplegia is used after about 20 minutes, the surgical procedure has to 
be interrupted for the instillation of cardioplegic solution which will add up to the total 
cardiopulmonary bypass time and aortic cross clamp time. Sometimes in order to avoid the use 
of additional dose of cardioplegia, the procedure will be hastened. 
Out of 60 cases, defibrillation at the end of surgery was required only in 5 cases. In those 
5 cases, 4 were aortic valve replacement and one was double valve replacement. The etiology for 
the cases which needed the defibrillation was found to have aortic stenosis in common. Hence it 
could be hypothesised that the need for defibrillation could be attributed to the left ventricular 
hypertrophy. 
This result coincides with the findings of R Ramanathan et al which reported that del 
Nido cardioplegia has potentially more benefits such as fewer doses of cardioplegia and less 
need for defibrillation compared to that of Buckberg’s cardioplegia. 
 Postoperatively ECG did not show any evidence of peroperative ischemic insult such as 
development of Q wave or any other significant changes consistent with the development of 
cardiac ischemia. 
Postoperatively ECHO was done and no Regional wall motion abnormality was detected 
in most of the cases which indicates a good myocardial protection. 
Out of 59 cases in which del Nido cardioplegia was used as an agent to arrest the heart 
while on cardiopulmonary bypass, 7 deaths were noted. The cause of death in all the 7 cases 
were primarily not attributed to use of del Nido cardioplegia and it is related to the surgical 
procedure.  
From this study it is clear that the myocardial protection afforded by del Nido 
Cardioplegia is better which is the key element in the outcome of cardiac surgery with 
cardiopulmonary bypass. 
 
  
 
 
 
 
 
 
LIMITATIONS OF THE STUDY 
 The sample size is less. 
 It is not a randomised control study 
 Del Nido cardioplegia is currently being used only in 2 surgical units. 
 The variations in the outcome of the surgery is due to individual variations in the 
operative techniques followed by different surgeons, postoperative management such as 
postoperative inotropic support, weaning of postoperative ventilator support,etc 
 Myocardial protection is assessed in this study with the help of the following indicators 
 Need for defibrillation 
 Postoperative inotropic support 
 Postoperative ICU stay 
 Postoperative ECG 
 Postoperative ECHO 
 The non – availability   the enzyme assay such as CK-MB, Troponin – T adds to the 
limitation of this study as it is warranted to clearly document regarding the myocardial 
protection. 
 Long term follow up is not available. 
 
 
 
 
 
 
 
CONCLUSION 
 From this study it could be concluded that del Nido cardioplegia could be safely used in 
adult cardiac surgery since it has the following advantages 
 Less frequent dosages needed 
 Less workflow interruptions 
 Smooth recovery from the cardiopulmonary bypass 
 Need for defibrillation is very less 
 Can be prepared locally in the hospital 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
FUTURE SCOPE OF THIS STUDY 
In future, 
 A prospective study has been planned. 
It will include a large group of patients from all age groups. 
Long term follow up to assess the late myocardial manifestations which may result 
from use of del Nido cardioplegia. 
 A comparative analysis between multidose and del Nido cardioplegia has to be done. 
 An analysis based on the data collected from various cardiac surgeons using del Nido 
cardioplegia to assess the potential benefits. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 INFORMED CONSENT FORM 
Title of the study: “Usefulness of del Nido cardioplegia in adult cardiac surgery”. 
Name of the Participant: 
______________________________________________________. 
Name of the Principal (Co-Investigator): Dr. R. Nandhakumar. 
__________________________________. 
Name of the Institution: Rajivgandhi govt. general hospital, Chennai. 
_____________________________________________________. 
Name and address of the sponsor / agency (ies) (if 
any):__________________________________ 
___________________________________________________________________________
______. 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it has been 
read to me). 
 Iwas free to ask any questions and they have been answered. I am over 18 years of age and, 
exercising myfree power of choice, hereby give my consent to be included as a participant in 
“Usefulness of Del Nido Cardiplegia in adult Cardiac surgery”. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have taken in the 
past________ months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this study.* 
7. I agree to cooperate with the investigator and I will inform him/her immediately if I suffer 
unusual symptoms. * 
8. I have not participated in any research study within the past _________month(s). * 
9. I have not donated blood within the past _______ months—Add if the study involves 
extensive blood sampling. * 
10. I am aware of the fact that I can opt out of the study at any time without having to give 
any reason and this will not affect my future treatment in this hospital. * 
11. I am also aware that the investigator may terminate my participation in the study at any 
time, for any reason, without my consent. * 
12. I hereby give permission to the investigators to release the information obtained from me 
as result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, 
and IEC. I understand that they are publicly presented. 
13. I have understand that my identity will be kept confidential if my data are publicly 
presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. By 
signing this consent form I attest that the information given in this document has been clearly 
explained to me and understood by me, I will be given a copy of this consent document. 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participantincompetent) 
Name _________________________ Signature_________________ 
Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name _________________________ Signature_________________ 
Date________________ 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name _________________________ Signature_________________ 
Date________________ 
 
 
 
Usefulness of delNidocardioplegia in adult cardiac surgery 
S.No. Name Ip No Age Sex Diagnosis Surgery  
CPB 
Duration 
Cross 
clamp 
duration 
No.of 
CP 
Defibrillation 
Yes/No  
Inotropic 
Support 
Postoperative 
ICU stay 
(days) 
Postoperative 
ECHO/ECG 
Postoperative 
period 
1 Tamilarasi 44578 43 F MS(S) MVR 110 72 1 NO MINIMAL 2 NORMAL Uneventful 
2 Ravi 59353 45 M MS/MR/AS DVR 187 149 2 1/2 NO MINIMAL 4 NORMAL Uneventful 
3 Malliga 73940 45 F MS(S) MVR 120 62 1 NO MINIMAL 3 NORMAL Uneventful 
4 Ramaiya 60644 55 M MS,AS DVR 179 150 3 NO MINIMAL 5 NORMAL Uneventful 
5 Veeran 61943 18 M MS, MR,AS,AR DVR 159 123 2 NO MINIMAL 4 NORMAL Uneventful 
6 Vanmathi 78839 51 F MRS MVR 90 63 1 NO         
7 Magamayi 78316 42 F RHDMS MVR 103 72 1 NO MINIMAL 2 NORMAL Uneventful 
8 Dhatvani 81435 40 F MS,MR MVR 124 53 1 NO MINIMAL 2 NORMAL Uneventful 
9 Balaji 61303 15 M MR,AR DVR 226 195 3 NO MINIMAL 5 NORMAL Uneventful 
10 Alagesan 84009 29 M MR(S) MVR 116 74 1 NO MINIMAL 2 NORMAL Uneventful 
11 Venketasan 81411 22 M MRS MVR 108 86 1 NO MINIMAL 3 NORMAL Uneventful 
12 Dhanavel 89094 45 M MS(S) MVR 108 76 1 NO MINIMAL 3 NORMAL Uneventful 
13 Parasuraman 92861 60 M AS(S) AVR 122 72 1 YES MINIMAL 3 NORMAL Uneventful 
14 Malar 92933 37 F MRS MVR 118 88 1 1/2 NO MINIMAL 3 NORMAL Uneventful 
15 Yasodha 77119 44 F MRS MVR 111 68 1 NO MINIMAL 3 NORMAL Uneventful 
16 Shamiam Begum 101374 48 F MRS MVR 240 101 1 1/2 NO         
17 Sathyaraj 103013 22 M MS,MR,AR DVR 162 106 2 NO MINIMAL 4 NORMAL Uneventful 
18 Arunachalam 99652 49 M RHDMS,AS DVR 246 185 3 YES MINIMAL 4 NORMAL Uneventful 
19 Anbukannan 107366 27 M RHD, MS, PHT MVR 178 72 1 NO MINIMAL 2 NORMAL Uneventful 
20 Thangaraj 92892 60 M RHD,AS AVR 503 155 3 YES         
21 Muniyammal 98849 30 F RHD,MS MVR 102 69 1 NO MINIMAL 2 NORMAL Uneventful 
22 Ayyammal 111070 25 F RHD,MS,MR MVR 133 98 2 NO MINIMAL 3 NORMAL Uneventful 
23 Malliga 112428 50 F AS,AR AVR 131 81 1 YES MINIMAL 4 NORMAL Uneventful 
24 Banumathi 108805 40 F RHD,MS(S) MVR 110 76 1 NO MINIMAL 2 NORMAL Uneventful 
25 Muhammed 114903 54 M RHD,AS AVR 104 73 1 NO MINIMAL 3 NORMAL Uneventful 
26 Thenmozhi 115308 30 M RHD,MS MVR 136 71 1 NO MINIMAL 4 NORMAL Uneventful 
27 Parashakthi 83604 23 F RHD,MS,AR DVR 180 139 2 NO MINIMAL 4 NORMAL Uneventful 
28 Sekar 122059 39 M RHD,AS,AR AVR 153 103 2 NO MINIMAL 4 NORMAL Uneventful 
29 Udhayakumar 108698 45 M RHD,MS MVR 102 66 1 NO MINIMAL 2 NORMAL Uneventful 
30 Lakshmi 105165 45 F RHD,MS MVR 205 118 2 NO         
31 Jeevitha 11099 23 F RHD,MS,AS,AR DVR 188 139 2 NO MINIMAL 4 NORMAL Uneventful 
32 Kannan 121888 60 M RHD,MS MVR 101 75 1 NO MINIMAL 2 NORMAL Uneventful 
33 Gowri 23348 37 F RHD,MS MVR 190 112 3 NO         
34 Thangaraj 116034 55 M RHD MS MVR 106 69 1 NO MINIMAL 2 NORMAL Uneventful 
35 Prabhu 118250 40 M RH MS AR DVR 172 120 2 NO MINIMAL 4 NORMAL Uneventful 
36 Tirupathy 1247 25 M RHD MS MVR 129 75 1 NO MINIMAL 2 NORMAL Uneventful 
37 Thulasidas 116157 52 M RHD AS MR DVR 581 239 4 NO         
38 Sasirekha 7145 25 F RHD MS MVR 136 90 1 1/2 NO MINIMAL 2 NORMAL Uneventful 
39 Panchali 122033 30 F RHD MS MVR 145 91 1 1/2 NO MINIMAL 2 NORMAL Uneventful 
40 Govindhammal 109852 55 F RHD MS MVR 175 100 1 1/2 NO         
41 Kaliammal 7098 45 F RHD MS MVR 106 69 1     NO MINIMAL 3 NORMAL Uneventful 
42 Priya 8988 19 F RHD MS MVR 100 72 1     NO MINIMAL 2 NORMAL Uneventful 
43 Jeeva 4803 45 F RHD MS MVR 138 92 1 1/2 NO MINIMAL 2 NORMAL Uneventful 
44 Selvi 89 44 F RHD MS MVR 121 88 1 1/2 NO MINIMAL 2 NORMAL Uneventful 
45 Ajithraj 7140 25 M RHD AS AVR 136 78 1     YES MINIMAL 3 NORMAL Uneventful 
46 Manjula 11296 43 F RHD MS MVR 99 61 1     NO MINIMAL 2 NORMAL Uneventful 
47 Pappathy 117785 50 F RHD MS MVR 148 96 1 1/2 NO MINIMAL 2 NORMAL Uneventful 
48 Babu 12800 48 M RHD MS MVR 138 89 1 1/2 NO MINIMAL 2 NORMAL Uneventful 
49 Prema 1153 21 F RHD MS AR DVR 146 107 2     NO MINIMAL 4 NORMAL Uneventful 
50 Inbaraj 13794 19 M RHD AS AR AVR 128 88 1 1/2 NO MINIMAL 3 NORMAL Uneventful 
51 Valli Kumar 12056 37 M RHD MS AS DVR 200 161 3     NO MINIMAL 4 NORMAL Uneventful 
52 Sumathi 11390 25 F RHD MS MVR 91 60 1     NO MINIMAL 2 NORMAL Uneventful 
53 Alex 12264 14 M RHD MS MVR 108 75 1     NO MINIMAL 2 NORMAL Uneventful 
54 Padmavathy 13976 32 F RHD MS AR DVR 150 130 2     NO MINIMAL 4 NORMAL Uneventful 
55 Raja 122954 27 M RHD MS AR DVR 264 226 4     NO MINIMAL 5 NORMAL Uneventful 
56 Jayalakshmi 7138 37 F RHD MS TS 
 MVR 
OTV 125 90 1 1/2 NO MINIMAL 3 NORMAL Uneventful 
57 Jeevanantham 16234 40 M RHD MS MVR 125 84 1 1/2 NO MINIMAL 2 NORMAL Uneventful 
58 Ramdoss 2072 24 M RHD MS MVR 173 120 2     NO MINIMAL 3 NORMAL Uneventful 
59 Backiyam 12120 52 F RHD MS MVR 102 45 1     NO MINIMAL 2 NORMAL Uneventful 
 
